7 news items
Immunic to Participate in Industry and Scientific Conferences in June
IMUX
28 May 24
"forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
IMUX
8 May 24
statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act
Immunic to Participate in Investor and Scientific Conferences in May
IMUX
6 May 24
substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
IMUX
1 May 24
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
IMUX
30 Apr 24
statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform
z5n84sbnrzbyhii
IMUX
4 Apr 24
release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided
leltykxapkvi3i 74j8auj0fui4bgpaucvyp2hq1
IMUX
4 Apr 24
release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided
- Prev
- 1
- Next